Sanofi Balansräkning Hälsa

Finansiell hälsa kriterier kontrolleras 6/6

Sanofi har ett totalt eget kapital på €77.9B och en total skuld på €17.9B vilket ger sin skuldsättningsgrad till 23%. Dess totala tillgångar och totala skulder är €132.8B respektive €54.9B. Sanofi s EBIT är €9.4B vilket gör dess räntetäckningsgrad 47.9. Den har kontanter och kortsiktiga investeringar på €7.6B.

Viktig information

23.01%

Skuldsättning i förhållande till eget kapital

€17.91b

Skuld

Räntetäckningsgrad	47.9x
Kontanter	€7.56b
Eget kapital	€77.86b
Summa skulder	€54.94b
Totala tillgångar	€132.80b

Nya uppdateringar om finansiell hälsa

Is Sanofi (EPA:SAN) Using Too Much Debt?

Dec 19

Recent updates

Sanofi (EPA:SAN) Is Increasing Its Dividend To €3.92

Apr 30

We think Sanofi's (EPA:SAN) CEO May Struggle To See Much Of A Pay Rise This Year

Apr 23

Beyfortus And Altuviiio Shine As Calculated Acquisitions And Innovations Fuel Growth

Nov 07 Strong performance in new medicines and Dupixent's market expansion boosts Sanofi's revenue growth and addresses unmet medical needs globally.

Sanofi's (EPA:SAN) Earnings Haven't Escaped The Attention Of Investors

Sep 10

Analys av finansiell ställning

Kortfristiga skulder: SAN s kortfristiga tillgångar ( €42.6B ) överstiger dess kortfristiga skulder ( €29.2B ).

Långfristiga skulder: SAN s kortfristiga tillgångar ( €42.6B ) överstiger dess långfristiga skulder ( €25.8B ).

Skuld till eget kapital Historik och analys

Skuldnivå: SAN s nettoskuld i förhållande till eget kapital ( 13.3% ) anses tillfredsställande.

Minska skulden: SAN s skuldsättningsgrad har minskat från 43.9% till 23% under de senaste 5 åren.

Skuldtäckning: SAN s skuld är väl täckt av operativt kassaflöde ( 50.7% ).

Räntetäckning: SAN s räntebetalningar på sin skuld är väl täckta av EBIT ( 47.9 x täckning).

Balansräkning

Upptäck friska företag

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2025/05/23 14:03
Aktiekurs vid dagens slut	2025/05/23 00:00
Intäkter	2025/03/31
Årlig intjäning	2024/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om den analysmodell som används för att generera denna rapport finns på vår Github-sida, vi har också guider om hur man använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Sanofi bevakas av 66 analytiker. 17 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
Kamla Singh	AlphaValue
John Eade	Argus Research Company
Odile Rundquist	Baader Helvea Equity Research

Sanofi Balansräkning Hälsa

Finansiell hälsa kriterier kontrolleras 6/6

Viktig information

Nya uppdateringar om finansiell hälsa

Is Sanofi (EPA:SAN) Using Too Much Debt?

Recent updates

Consensus EPS estimates increase by 18%

Sanofi (ENXTPA:SAN) entered into a definitive merger agreement to acquire Vigil Neuroscience, Inc. (NasdaqGS:VIGL) for approximately $380 million.

Upcoming dividend of €3.92 per share

Sanofi Appoints Clotilde Delbos as Chairwoman of the Compensation Committee

Clayton, Dubilier & Rice Fund XII a fund managed by Clayton, Dubilier & Rice, LLC acquired 50% stake in Opella Healthcare Group SAS from Sanofi (ENXTPA:SAN) for around €10 billion.

Sanofi (EPA:SAN) Is Increasing Its Dividend To €3.92

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 11%

We think Sanofi's (EPA:SAN) CEO May Struggle To See Much Of A Pay Rise This Year

Consensus EPS estimates increase by 11%

Sanofi's (EPA:SAN) Upcoming Dividend Will Be Larger Than Last Year's

Sanofi's Respiratory Pipeline Advances with New Data in Asthma and Plans for New Clinical Studies in COPD

Sanofi Announces Tolebrutinib Phase 3 Data Published in NEJM Demonstrate Benefit on disability Progressive Forms

Sanofi (EPA:SAN) Is Paying Out A Larger Dividend Than Last Year

Consensus EPS estimates fall by 12%

Regeneron Pharmaceuticals, Inc. and Sanofi Announce Ministry of Health, Labour and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab)

Sanofi Announces Tolebrutinib Regulatory Submission Accepted for Priority Review in the US for Patients with Multiple Sclerosis

Sanofi (EPA:SAN) Is Increasing Its Dividend To €3.92

Dividend increased to €3.92

Sanofi Adopts FDA-Selected Flu Strains to Ensure Readiness for the 2025-26 Flu Season

Sanofi, Annual General Meeting, Apr 30, 2025

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Dupixent Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented At Aad

Sanofi Announces New Duvakitug Data Reinforce Best-In-Class Potential in Ulcerative Colitis and Crohn's Disease

Sanofi Announces Sarclisa Approval in Japan for Patients with Newly Diagnated Multiple Myeloma

Sanofi's (EPA:SAN) Earnings Offer More Than Meets The Eye

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)

Sanofi Announces Update on E.Mbrace Phase 3 Clinical Study

Full year 2024 earnings: EPS and revenues miss analyst expectations

Sanofi Reports Consolidated Impairment of Intangible Assets for the Fourth Quarter Ended December 31, 2024

Sanofi Announces Sarclisa Approval in the EU as the First Anti-CD38 Therapy in Combination with Standard-Of-Care VRd to Treat Transplant-ineligible Newly Diagnated Multiple Myeloma

Sanofi Announces Sarclisa Obtains First Approval in China for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma

Sanofi Announces Board Changes

Is Sanofi (EPA:SAN) Using Too Much Debt?

Sanofi Announces Two Combination Vaccine Candidates for Prevention of Influenza and COVID-19 Granted Fast Track Designation in the US

Frantz Law Group Files Oceanside Unified School District Lawsuit Against Eli Lily, Novo Nordisk, Sanofi, Express Scripts, CVS Caremark, and Optum RX for Insulin Pricing Scheme

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Review the Resubmission of the Supplemental Biologics License Application for Dupixent®?

Beyfortus And Altuviiio Shine As Calculated Acquisitions And Innovations Fuel Growth

Regeneron Pharmaceuticals, Inc. and Sanofi Receive European Union Approval For Dupixent In Young Children With Eosinophilic Esophagitis

Sanofi Announces Beyfortus (Nirsevimab) to Be Broadly Available for Babies Born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon This Fall

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Sanofi Reportedly in Talks with French Government over Opella Sale

Clayton, Dubilier & Rice Reportedly Nears €15 Billion Deal for Sanofi Consumer Health Unit

Sanofi Healthcare Bidders Reportedly Revising Offers over Talc Concerns

Sanofi Reportedly Seeks Revised Proposals for Opella

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Sanofi to Report Q2, 2025 Results on Jul 31, 2025

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Approves Dupixent (Dupilumab) as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps

Sanofi's (EPA:SAN) Earnings Haven't Escaped The Attention Of Investors

Sanofi Announces Tolebrutinib Meet Primary Endpoints in HERCULES Phase 3 Study

Teva Pharmaceuticals and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease

Sanofi Ships U.S. Influenza Vaccines for the 2024/25 Season

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in the European Union as the First-Ever Targeted Therapy for Patients with COPD

Sanofi to Present New Data from its Hemophilia Portfolio at the 32nd Congress of the International Society on Thrombosis and Haemostasis

Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial

Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application (sBLA) for Dupixent

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts Dupixent®? (Dupilumab) Sbla for Treatment of Copd with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. and Sanofi Announces the Ministry of Health, Labor and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab) for the Treatment of Chronic Spontaneous Urticaria

Regeneron Pharmaceuticals, Inc. and Sanofi Announce That U.S. Food and Drug Administration Approves Dupixent®? (Dupilumab) for the Treatment of Children Aged 1 Year and Older with Eosinophilic Esophagitis

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Updates the Label for Dupixent (Dpilumab)

Regeneron Pharmaceuticals, Inc. and Sanofi Provide Update on Dupixent®? (Dupilumab) sBLA for Chronic Spontaneous Urticaria

Sanofi Reportedly Explores Potential Acquisition of Mirati Therapeutics

Sanofi S.A. and Sobi Announce Once-Weekly ALTUVIIIO Approved in Japan as A New Class of Factor VIII Therapy for Hemophilia A

SK Bioscience and Sanofi Announce Positive Results from Phase II Study of 21-Valent Pneumococcal Conjugate Vaccine Candidate

Analys av finansiell ställning

Skuld till eget kapital Historik och analys

Balansräkning

Upptäck friska företag

Företagsanalys och finansiella data Status

Datakällor

Analysmodell och snöflinga

Industri- och sektormått

Källor för analytiker